Lower cost through shorter and smaller trials
Improved likelihood of successful outcome of trial and drug approval for desired claims
Improved clinical adoption due to clearer patient benefit vs. risk profile
For example, in Alzheimer’s disease, only 1 of 244 compounds tested against the disease in clinical trials from 2002 to 2012 received FDA approval. 1 Of 83 Phase III clinical trials, not one met its primary endpoints. 2 Neurological drugs have the longest NDA review process. 3
A recent clinical trial showed that 40% of patients who applied to participate didn’t have the disease, despite showing signs of early dementia. In another relevant Phase III Alzheimer’s trial, up to 25% of patients did not have the target for which the drug was expected to act. 4
Differences in subjective endpoints are often small and require long time frames and large cohorts to achieve statistical and clinical significance. 5
We only apply widely accepted and validated published algorithms. Proprietary algorithms do not offer transparency and traceability for drug regulatory approval process.
We work with you to select the best biomarkers and assessment method for your trial. Our fast processing and modular computational architectures allow us to offer tailored solutions in a scalable and multipurpose way.
Our expertise is focused on neurodegenerative diseases -such as Alzheimer diseases and Multiple sclerosis- brain cancer and other CNS diseases. Ask us about the CNS disease you are working on.
Our focus is your focus: Successful completion of the clinical trial as quickly and inexpensively as possible leading to drug regulatory approval and commercialization. We bring science and technology to the needs of the pharma industry.
There has been no real success in drug development for a disease suffered by nearly 35.6 million people worldwide. Quantitative neuroimaging may make the difference.
MS is a paradigmatic example of how neuroimaging has accelerated new therapy development. Diagnosis and clinical trials are inconceivable without brain imaging for MS.
Although it is a heterogenous disease containing a variety of types of brain tumors, neuroimaging lies at the heart of the evaluation criteria.
Neuroimaging biomarkers are applied to a number of neurological disease. Some notorious examples are epilepsia, schizophrenia and autism, among others.
Chief Operating Officer
Big data architect
Information and security
High performance computing
Design and marketing
CFO & General Manager
Edif.Bioinnovación. Parque Tecnológico de Andalucía , Málaga. Spain.
+34 951 136 978 / +34 653 937 331